AbbVie Inc (ABBV)vsIndivior PLC Ordinary Shares (INDV)
ABBV
AbbVie Inc
$211.32
+3.64%
HEALTHCARE · Cap: $360.63B
INDV
Indivior PLC Ordinary Shares
$36.78
+7.70%
HEALTHCARE · Cap: $4.18B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 4836% more annual revenue ($61.16B vs $1.24B). INDV leads profitability with a 17.0% profit margin vs 6.9%. INDV trades at a lower P/E of 20.9x. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
INDV
Buy62
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$211.32
$47.90 premium
Margin of Safety
-51.5%
Fair Value
$22.49
Current Price
$36.78
$14.29 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Strong operational efficiency at 37.1%
Earnings expanding 376.2% YoY
19.7% revenue growth
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : INDV
The strongest argument for INDV centers on Operating Margin, EPS Growth, Revenue Growth. Profitability is solid with margins at 17.0% and operating margin at 37.1%. Revenue growth of 19.7% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : INDV
The primary concerns for INDV are Free Cash Flow.
Key Dynamics to Monitor
ABBV profiles as a value stock while INDV is a growth play — different risk/reward profiles.
INDV carries more volatility with a beta of 1.21 — expect wider price swings.
INDV is growing revenue faster at 19.7% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 62/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Indivior PLC Ordinary Shares
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Indivior PLC, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company is headquartered in North Chesterfield, Virginia.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?